Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilization in Treatment of Anaemia in Patients with Chronic Kidney Disease

• Hayashi Takahiro

  Department of Clinical Pharmacy, School of Medicine, Fujita Health University Faculty of Pharmacy, Meijo University

• Nagamatsu Tadashi

  Faculty of Pharmacy, Meijo University

• Matsushita Ayako

  Faculty of Pharmacy, Meijo University

• Mizuno Tomohiro

  Faculty of Pharmacy, Meijo University Department of Nephrology, School of Medicine, Fujita Health University

• Nishibe Seira

  Department of Clinical Pharmacy, School of Medicine, Fujita Health University

• Noguchi Ayaka

  Faculty of Pharmacy, Meijo University

• Kato Rina

  Faculty of Pharmacy, Meijo University

• Toda Takahiro

  Department of Clinical Pharmacy, School of Medicine, Fujita Health University

• Tanaka Junko

  Department of Clinical Pharmacy, School of Medicine, Fujita Health University

• Takahashi Hiroshi

  Division of Medical Statistics, Fujita Health University

• Hayashi Hiroki

  Department of Nephrology, School of Medicine, Fujita Health University

• Yuzawa Yukio

  Department of Nephrology, School of Medicine, Fujita Health University

• Yamada Shigeki

  Department of Clinical Pharmacy, School of Medicine, Fujita Health University

書誌事項

タイトル別名

• Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilisation in Treatment of Anaemia in Patients with Chronic Kidney Disease

抄録

Comparative studies of the potency of long- and short-acting erythropoiesis-stimulating agents (L-ESAs and S-ESAs) on erythropoietic activity in patients with chronic kidney disease without dialysis have not been performed, although L-ESAs are used in many countries. We performed a retrospective analysis of non-dialysis (ND) patients who had received L-ESA or S-ESA. More days were needed for the S-ESA-treated group (368 d) to reach the haemoglobin (Hb) reference range than for the L-ESA-treated group (126 d). Therefore, we investigated risk factors that influence the period until the Hb level reaches the reference range. Patients were classified into two groups by the period until the Hb level was stabilised within the reference range: the short- and long-term group. Two risk factors for delayed Hb stabilisation were identified: age ≥60 years; and administration of an S-ESA for initial treatment. These findings suggest that the Hb level should be carefully monitored during ESA therapy in elderly ND patients, and that the ESA dose should be increased or L-ESA therapy should be utilised to treat renal anaemia.

収録刊行物

• Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ

  Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ 38 (5), 740-745, 2015

  公益社団法人 日本薬学会

キーワード

• erythropoiesis-stimulating agent
• haemoglobin stabilization
• risk factor
• anaemia
• chronic kidney disease

詳細情報

• CRID: 1390001204631411584
• NII論文ID: 130005068083
• NII書誌ID: AA10885497
• DOI: 10.1248/bpb.b14-00844
• ISSN: 13475215
• ISSN: 09186158
• NDL書誌ID: 026355323
• PubMed: 25740003
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I026355323
• Web Site: https://www.jstage.jst.go.jp/article/bpb/38/5/38_b14-00844/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2016010363
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可